drugset / Trial / NCT07496229
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.
Timeline
- Start
- 2026-04-15
- Primary completion
- 2029-09
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | GW5282 | Unknown | 40 mg | — |
| Subject | Golidocitinib | Small molecule | 150 mg | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Vincristine | Small molecule | — | — |